| From bench to bedside–preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis (1H-indazole) ruthenate (III)](KP1019 or FFC14A) CG Hartinger, S Zorbas-Seifried, MA Jakupec, B Kynast, H Zorbas, ... Journal of inorganic biochemistry 100 (5-6), 891-904, 2006 | 1243 | 2006 |
| Bioorganometallic chemistry—from teaching paradigms to medicinal applications CG Hartinger, PJ Dyson Chemical Society Reviews 38 (2), 391-401, 2009 | 1114 | 2009 |
| KP1019, a new redox‐active anticancer agent–Preclinical development and results of a clinical phase I study in tumor patients CG Hartinger, MA Jakupec, S Zorbas‐Seifried, M Groessl, A Egger, ... Chemistry & biodiversity 5 (10), 2140-2155, 2008 | 1098 | 2008 |
| Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology AR Timerbaev, CG Hartinger, SS Aleksenko, BK Keppler Chemical reviews 106 (6), 2224-2248, 2006 | 807 | 2006 |
| Antitumour metal compounds: more than theme and variations MA Jakupec, M Galanski, VB Arion, CG Hartinger, BK Keppler Dalton transactions, 183-194, 2008 | 710 | 2008 |
| Challenges and opportunities in the development of organometallic anticancer drugs CG Hartinger, N Metzler-Nolte, PJ Dyson Organometallics 31 (16), 5677-5685, 2012 | 626 | 2012 |
| Anticancer activity of metal complexes: involvement of redox processes U Jungwirth, CR Kowol, BK Keppler, CG Hartinger, W Berger, P Heffeter Antioxidants & redox signaling 15 (4), 1085-1127, 2011 | 626 | 2011 |
| The development of RAPTA compounds for the treatment of tumors BS Murray, MV Babak, CG Hartinger, PJ Dyson Coordination Chemistry Reviews 306, 86-114, 2016 | 536 | 2016 |
| Structure–activity relationships for ruthenium and osmium anticancer agents–towards clinical development SM Meier-Menches, C Gerner, W Berger, CG Hartinger, BK Keppler Chemical Society Reviews 47 (3), 909-928, 2018 | 459 | 2018 |
| Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium (II)− arene compounds A Casini, C Gabbiani, F Sorrentino, MP Rigobello, A Bindoli, TJ Geldbach, ... Journal of medicinal chemistry 51 (21), 6773-6781, 2008 | 358 | 2008 |
| Gold (III) compounds as anticancer agents: relevance of gold–protein interactions for their mechanism of action A Casini, C Hartinger, C Gabbiani, E Mini, PJ Dyson, BK Keppler, ... Journal of inorganic biochemistry 102 (3), 564-575, 2008 | 341 | 2008 |
| The ruthenium (II)–arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53–JNK pathways S Chatterjee, S Kundu, A Bhattacharyya, CG Hartinger, PJ Dyson JBIC Journal of Biological Inorganic Chemistry 13 (7), 1149-1155, 2008 | 325 | 2008 |
| Opening the lid on piano-stool complexes: an account of ruthenium (II)–arene complexes with medicinal applications AA Nazarov, CG Hartinger, PJ Dyson Journal of Organometallic Chemistry 751, 251-260, 2014 | 308 | 2014 |
| Resistance against novel anticancer metal compounds: differences and similarities P Heffeter, U Jungwirth, M Jakupec, C Hartinger, M Galanski, L Elbling, ... Drug resistance updates 11 (1-2), 1-16, 2008 | 304 | 2008 |
| Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy M Pongratz, P Schluga, MA Jakupec, VB Arion, CG Hartinger, G Allmaier, ... Journal of Analytical Atomic Spectrometry 19 (1), 46-51, 2004 | 296 | 2004 |
| Structure−Activity Relationships for NAMI-A-type Complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = Imidazole, Indazole, 1,2,4-Triazole, 4-Amino-1,2,4 … M Groessl, E Reisner, CG Hartinger, R Eichinger, O Semenova, ... Journal of medicinal chemistry 50 (9), 2185-2193, 2007 | 285 | 2007 |
| Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study F Lentz, A Drescher, A Lindauer, M Henke, RA Hilger, CG Hartinger, ... Anti-cancer drugs 20 (2), 97-103, 2009 | 276 | 2009 |
| Redox behavior of tumor-inhibiting ruthenium (III) complexes and effects of physiological reductants on their binding to GMP P Schluga, CG Hartinger, A Egger, E Reisner, M Galanski, MA Jakupec, ... Dalton transactions, 1796-1802, 2006 | 246 | 2006 |
| Influence of the Spacer Length on the in Vitro Anticancer Activity of Dinuclear Ruthenium−Arene Compounds MG Mendoza-Ferri, CG Hartinger, RE Eichinger, N Stolyarova, K Severin, ... Organometallics 27 (11), 2405-2407, 2008 | 218 | 2008 |
| Development of anticancer agents: wizardry with osmium M Hanif, MV Babak, CG Hartinger Drug Discovery Today 19 (10), 1640-1648, 2014 | 216 | 2014 |
Muhammad HanifUniversity of AucklandVerified email at auckland.ac.nz
